Doliracetam
Little-known experimental racetam from a 1982 patent; practically no research data exists on it.
Pharmacology
Contents
DETAILED OVERVIEW
What is Doliracetam?
Doliracetam is an experimental compound grouped with the racetams. It was first described in a 1982 patent. It is not approved as a medicine anywhere, and it is not sold as a dietary supplement either. It is one of the most poorly documented racetams, so today it is mostly a curiosity from the history of science.
Improved memory and anti-seizure effects have been suggested for it, but these are only patent claims: independent research has not confirmed them, and practically no studies have been done on humans. A mechanism of action has never been established, and the scientific literature contains no animal or human study dedicated to it. Its side effects and interactions with medicines are unknown. It should be avoided in pregnancy and breastfeeding, because there are no safety data.
Mechanism
Uncharacterized (patent-claimed neuroanabolic)
Half-life
N/A
Onset
N/A
Legal status
Unapproved, unmarketed; reference material only
There is virtually no community or anecdotal experience with doliracetam. It is one of the most poorly documented racetams, rarely sourced and almost never discussed in trip-report or stack communities. The little that circulates online is extrapolated from the patent language or from other racetams rather than from real, repeated user reports, so any claimed effect should be treated with strong skepticism. This entry is a reference, not a usage guide.
⚠ Not clinical evidence – based on user accounts.
Receptor profile
- Cholinergic transmissionWeak
- AMPA glutamate receptorsWeak
- Neuronal plasticityWeak
Safety
Side effects, stop signs, contraindications
Side effects · 3
- With virtually no human data, the side-effect profile is unknown; racetam-like effects such as headache are plausible but unconfirmed
- Theoretical choline-depletion headache, as with other racetams; a choline source may help in principle, but this is unproven
- Unknown long-term safety: never marketed and with no clinical development on record
Contraindications · 3
- Pregnancy and breastfeeding: no safety data, should be avoided
- Not a medicine: human clinical trials have not established its safety, any use is experimental
- Unknown drug interactions: the mechanism is uncharacterized, so co-administration risk cannot be estimated
Related Nootropics
Same therapeutic category
FAQ
FAQ
Doliracetam is an obscure experimental compound first described in a 1982 pharmaceutical patent, which claimed it might help with memory and have anti-seizure properties. Those claims come only from the patent itself, and there's essentially no human testing to back them up. Today it's mostly a historical and structural curiosity rather than something with an established practical use.
Telegram
Have a question about Doliracetam?
Reach out to us on Telegram for a personalized stack. We'll be happy to help.
Personalized consultation
Want a detailed conversation tailored to your data?
Fill out the prep intake form (your goals, training and health data), and the advisor prepares from it to give genuinely personalized guidance.
Fill out the form~5–7 min · prep questionnaire · confidential · GDPR-compliant
Structure & chemistry
The information here is strictly for educational and scientific purposes. It does not replace medical advice or clinical consultation, and it does not encourage illegal substance or pharmaceutical use. Data is sourced. When in doubt, consult your doctor.